| Author | Ferreira, Clarissa de Castro | |
| Author | Azevedo, Ana Carolina Campi | |
| Author | Pascoal, Vanessa Peruhype Magalhāes | |
| Author | Reis, Jordana Grazziela Alves Coelho dos | |
| Author | Antonelli, Lis Ribeiro do Valle | |
| Author | Torres, Karen Cecília de Lima | |
| Author | Freire, Larissa Chaves | |
| Author | Rocha, Ismael Artur da Costa | |
| Author | Oliveira, Ana Cristina Vanderley | |
| Author | Maia, Maria de Lourdes de Sousa | |
| Author | Lima, Sheila Maria Barbosa de | |
| Author | Domingues, Carla Magda | |
| Author | Carvalho, Andréa Teixeira de | |
| Author | Martins Filho, Olindo Assis | |
| Author | Mota, Lícia Maria Henrique da | |
| Access date | 2019-04-22T11:59:34Z | |
| Available date | 2019-04-22T11:59:34Z | |
| Document date | 2019 | |
| Citation | FERREIRA, Clarissa de Castro et al. Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis. Arthritis Research and Therapy, v. 21, n. 1, p. 1-12, 2019. | pt_BR |
| ISSN | 1478-6362 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/32628 | |
| Language | por | pt_BR |
| Publisher | BMC | pt_BR |
| Rights | open access | pt_BR |
| Subject in Portuguese | Imunidade celular | pt_BR |
| Subject in Portuguese | Terapia imunomoduladora | pt_BR |
| Subject in Portuguese | Anticorpos neutralizantes | pt_BR |
| Subject in Portuguese | Artrite reumatoide | pt_BR |
| Title | Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis | pt_BR |
| Type | Article | pt_BR |
| DOI | 10.1186/s13075-019-1854-6 | |
| Abstract | Background: The 17DD-yellow fever (YF) vaccine induces a long-lasting protective immunity, resulting from humoral and cellular immunological memory. The treatment of rheumatoid arthritis (RA) patients with disease-modifying anti-rheumatic drugs (DMARD) may affect pre-existing 17DD-vaccine protective immunity and increase the risk of acquiring YF infection. Our goal was to determine whether DMARD would affect the duration of YFspecific protective immunity in RA patients. Methods: A total of 122 RA patients, previously immunized with the 17DD-YF vaccine (1–5, 5–9, and ≥ 10 years) and currently under DMARD therapy, were enrolled in the present investigation. Immunomodulatory therapy encompasses the use of conventional synthetic DMARD alone (csDMARD) or combines with biological DMARD (cs+bDMARD). A total of 226 healthy subjects were recruited as a control group (CONT). Neutralizing antibody responses were measured by a plaque-reduction neutralization test (PRNT), and cellular immunity was evaluated by an in vitro 17DD-YF-specific peripheral blood lymphoproliferative assay. Results: The data demonstrated that csDMARD therapy did not affect the duration of protective immunity induced by the 17DD-YF vaccine compared to that of CONT, as both presented a significant time-dependent decline at 10 years after vaccination. Conversely, cs+bDMARD therapy induced a premature depletion in the main determinants of the vaccine protective response, with diminished PRNT seropositivity levels between 5 and 9 years and impaired effector memory in CD8+ T cells as early as 1–5 years after 17DD-YF vaccination. Conclusions: These findings could support changing the vaccination schedule of this population, with the possibility of a planned booster dose upon the suspension of bDMARD in cases where this is allowed, even before 10 years following 17DD-YF vaccination. The benefit of a planned booster dose should be evaluated in further studies. Trial registration: RBR-946bv5. Date of registration: March 05, 2018. Retrospectively registered. | pt_BR |
| Affilliation | Universidade de Brasília. Hospital Universitário de Brasília. Departamento de Reumatologia. Brasília, DF, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Universidade de Brasília. Hospital Universitário de Brasília. Departamento de Reumatologia. Brasília, DF, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de Imunizações. Brasília, DF, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brasil. | pt_BR |
| Affilliation | Universidade de Brasília. Hospital Universitário de Brasília. Departamento de Reumatologia. Brasília, DF, Brasil. | pt_BR |
| Subject | Cellular immunity | pt_BR |
| Subject | Immunomodulatory therapy | pt_BR |
| Subject | Neutralizing antibodies | pt_BR |
| Subject | Rheumatoid arthritis | pt_BR |
| Subject | Yellow fever vaccine | pt_BR |
| Subject | Vacina contra febre amarela | pt_BR |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
